Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.67 Consensus Price Target from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $17.67.

ATEC has been the subject of a number of research reports. Barclays upped their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. Finally, Piper Sandler raised their price target on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles sold 12,691 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total value of $135,032.24. Following the completion of the transaction, the chief executive officer now directly owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This represents a 0.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Scott Lish sold 23,183 shares of Alphatec stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $12.03, for a total transaction of $278,891.49. Following the sale, the chief operating officer now directly owns 844,494 shares in the company, valued at $10,159,262.82. The trade was a 2.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 337,083 shares of company stock valued at $3,825,680 in the last 90 days. Insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ATEC. GAMMA Investing LLC boosted its position in shares of Alphatec by 38,433.3% during the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock valued at $228,000 after purchasing an additional 2,306 shares in the last quarter. Comerica Bank boosted its holdings in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after buying an additional 1,248 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Alphatec in the 4th quarter worth about $29,000. Nisa Investment Advisors LLC increased its stake in shares of Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 4,234 shares in the last quarter. Finally, Quarry LP lifted its position in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after acquiring an additional 2,375 shares during the period. Institutional investors own 66.35% of the company’s stock.

Alphatec Trading Up 2.3 %

NASDAQ ATEC opened at $9.75 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The stock’s 50-day simple moving average is $10.47 and its two-hundred day simple moving average is $9.32. Alphatec has a twelve month low of $4.88 and a twelve month high of $13.79. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -7.62 and a beta of 1.20.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. Research analysts forecast that Alphatec will post -1.08 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.